COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...

Full description

Saved in:
Bibliographic Details
Main Authors: E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
Format: Article
Language:Russian
Published: IRBIS LLC 2017-08-01
Series:Фармакоэкономика
Subjects:
chronic obstructive pulmonary disease
copd
long-acting beta-agonists
laba
long-acting anticholinergics
laac
vilantererol
umeclidinum bromide
olodaterol
tiotropium bromide
fixed combination
cost minimization analysis
cost-effectiveness analysis
budget impact analysis
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/196
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items